Modern Chinese Medicine Group Co (HKSE:01643) 3-Year EBITDA Growth Rate : -9.40% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Modern Chinese Medicine Group Co 3-Year EBITDA Growth Rate?

Modern Chinese Medicine Group Co's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.05.

During the past 12 months, Modern Chinese Medicine Group Co's average EBITDA Per Share Growth Rate was -43.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -9.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Modern Chinese Medicine Group Co was 34.60% per year. The lowest was -9.40% per year. And the median was 24.75% per year.

Competitive Comparison of Modern Chinese Medicine Group Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Modern Chinese Medicine Group Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Modern Chinese Medicine Group Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modern Chinese Medicine Group Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Modern Chinese Medicine Group Co's 3-Year EBITDA Growth Rate falls into.

Modern Chinese Medicine Group Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Modern Chinese Medicine Group Co (HKSE:01643) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Modern Chinese Medicine Group Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Modern Chinese Medicine Group Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Modern Chinese Medicine Group Co (HKSE:01643) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modern Chinese Medicine Group Co Ltd (HKSE:01643) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88 Jinwei Road, Hebei, Chengde, CHN, 068150

Website

http://www.cdysjdyy.com

Modern Chinese Medicine Group Co Ltd is engaged in the production of proprietary Chinese medicine. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include Vigour and Vitality Supplement Pill, Circulation Enhancement Pill, Cardiotonic Enhancement Capsule, Kidney Invigoration Pill, Heart Wellness Capsule, Menstrual Discomfort Relief Pill, Liver Detox Tablet, and Additional Ingredient Huoxiang ZhengQi Pill and Fever-removing and Detoxification Pill. The Group has one operating segment of its business as a whole as the production of PCM. Geographically, the majority is from PRC.

Executives

Sun Xinlei	2201 Interest of corporation controlled by you
Xian Dai Sheng Wu Ke Ji Ji Tuan Kong Gu You Xian Gong Si	2101 Beneficial owner
Xie Wei	2201 Interest of corporation controlled by you

Modern Chinese Medicine Group Co (HKSE:01643) Headlines

No Headlines